Mission Statement, Vision, & Core Values of Exagen Inc. (XGN)

A company's Mission, Vision, and Core Values are not just posters on a wall; they are the strategic scaffolding that either supports or crumbles under financial pressure, and for Exagen Inc. (XGN), this framework is critical as they push toward profitability.

Their full-year 2025 revenue guidance of between $65 million and $70 million, paired with a Q3 2025 net loss of $7.087 million, shows a business at a pivotal inflection point, so how exactly do their stated values-like providing clarity in autoimmune disease decision-making-map to the hard numbers on a balance sheet?

You need to know if the commitment to innovation, which drove the AVISE CTD test's trailing-twelve-month average selling price (ASP) to $441 per test in Q3 2025, is defintely a sustainable growth engine or just a one-time spike.

Exagen Inc. (XGN) Overview

You're looking for a clear, no-nonsense assessment of Exagen Inc., and the takeaway is simple: this is a diagnostics company that has successfully carved out a profitable niche in the complex world of autoimmune disease testing. Founded in 2002 and headquartered in Vista, California, Exagen is a commercial-stage life sciences company focused on transforming patient care by providing innovative, actionable diagnostic and prognostic solutions for conditions like lupus and rheumatoid arthritis (RA).

Their core business revolves around the proprietary AVISE testing portfolio, which helps rheumatologists differentiate between various connective tissue diseases (CTDs) earlier and more accurately than traditional methods. The flagship product, AVISE CTD, is the key revenue driver. They've been consistently expanding their offerings, for example, by adding seronegative RA markers for anti-PAD4 to the AVISE CTD panel in the third quarter of 2025.

For the full fiscal year 2025, Exagen has guided for total revenue between $65 million and $70 million. That's a defintely solid performance, showing strong market adoption for their specialized testing. Here's the quick math on their main product: the trailing-twelve-month (TTM) Average Selling Price (ASP) for AVISE CTD reached $441 per test as of Q3 2025, an increase of $37 per test compared to Q3 2024.

To understand the full scope of their journey and how they got here, you can find more detail on their history and business model at Exagen Inc. (XGN): History, Ownership, Mission, How It Works & Makes Money.

Q3 2025 Financial Performance: Record Revenue and Margin Expansion

The latest financial report, covering the third quarter ended September 30, 2025, shows Exagen is executing its growth strategy well. The company delivered a record total revenue of $17.2 million for the quarter. This wasn't a fluke; it represents a significant 38% increase year-over-year compared to the third quarter of 2024.

The growth isn't just about price increases, either. The volume of their main product, AVISE CTD, grew by 16% compared to the same quarter last year. That tells me rheumatologists are increasingly relying on their diagnostic tools. Also, the gross margin improved to 58.4% in Q3 2025, up from 55.8% in Q3 2024, which reflects better operational efficiency and pricing strategies.

• Q3 2025 Revenue: $17.2 million.
• Year-over-Year Revenue Growth: 38%.
• AVISE CTD Volume Growth: 16%.
• Cash and Equivalents: $35.7 million at quarter end.

The company is also tightening its belt on the expense side. The adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) loss was significantly reduced to $(1.9) million for the quarter, a marked improvement from the $(4.0) million loss in Q3 2024. Management even expects to achieve positive adjusted EBITDA in the fourth quarter of 2025 if they hit the high end of their revenue guidance.

Exagen's Position as an Autoimmune Diagnostics Leader

Exagen Inc. is consistently recognized as a leading provider of innovative autoimmune testing solutions in the diagnostics industry. They are not just another lab; their focus on proprietary biomarkers (a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease) and a full suite of AVISE-branded tests for diagnosis, prognosis, and monitoring gives them a competitive edge.

This leadership position is earned through continuous innovation, like the commercial launch of new seronegative RA markers in Q3 2025, and their ongoing research into platforms like lupus nephritis. They are transforming the care continuum for patients with chronic and debilitating autoimmune conditions by providing clarity in clinical decision-making. Their success is driven by the clinical value their tests provide to rheumatologists, enabling earlier and more accurate diagnoses, which is critical for patient outcomes. To truly grasp the strategic depth of their success, you need to look closer at the underlying mission and values that fuel this innovation.

Exagen Inc. (XGN) Mission Statement

You're looking for the bedrock of Exagen Inc.'s strategy, and honestly, it's all in the mission statement. It's more than just a catchy phrase; it's the operational blueprint that guides their investment in research and their sales execution. The core mission is straightforward: To provide clarity in autoimmune disease decision-making and improve clinical outcomes through its innovative testing portfolio. This mission is the lens through which we should view their financial performance and future growth prospects.

A mission like this is crucial because it focuses capital allocation. It means every dollar of the projected 2025 full-year revenue-expected to be between $65 million and $70 million-is theoretically tied back to delivering a diagnostic test that helps a clinician make a better, faster decision for a patient. That's a strong, patient-centric focus that defintely resonates with long-term value creation, even as they work toward achieving positive adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) by the fourth quarter of 2025. You can see how this focus impacts their bottom line in our deeper dive: Breaking Down Exagen Inc. (XGN) Financial Health: Key Insights for Investors.

Core Component 1: Providing Clarity in Autoimmune Disease Decision-Making

The first component is about translating complex biological signals into actionable information for physicians, primarily rheumatologists. Autoimmune diseases like lupus and rheumatoid arthritis are notoriously difficult to diagnose early; a misdiagnosis can delay effective treatment for years. Exagen Inc. addresses this by creating diagnostic and prognostic solutions that cut through the noise, giving doctors a clear path forward.

Here's the quick math on impact: Exagen's flagship product, AVISE CTD, has seen its trailing twelve-month average selling price (ASP) expand to $441 per test as of the third quarter of 2025. This increase reflects the growing clinical value and reimbursement for the high-quality, actionable data the test provides. When a test is priced this high and volume is still growing-Q3 2025 saw a 16% increase in AVISE CTD test volume year-over-year-it tells you the market believes in the clarity it delivers. It's a high-value service, plain and simple.

Core Component 2: Innovative Testing Portfolio

The mission's commitment to an 'innovative testing portfolio' is where Exagen Inc. maps its research and development (R&D) spend to tangible product launches. Innovation isn't just a buzzword here; it's a necessity in the rapidly evolving diagnostics space. This component is the engine for their revenue growth, which hit a record $17.2 million in the third quarter of 2025, a 38% jump from the same quarter last year.

The company is constantly enhancing its offerings, which is the real opportunity for investors. They are not sitting still. For instance, at the end of Q3 2025, Exagen commercially launched new seronegative rheumatoid arthritis (RA) markers for anti-PAD4, which is a significant enhancement to the AVISE CTD panel. This kind of consistent, incremental innovation is what drives the expansion of their total addressable market and helps secure their position as a niche leader.

• Launch new biomarkers for market expansion.
• Invest in R&D for next-generation diagnostics.
• Maintain CLIA-certified, CAP-accredited laboratory standards.

Core Component 3: Improving Clinical Outcomes

Ultimately, the mission circles back to the patient. 'Improving clinical outcomes' is the ethical and commercial justification for everything Exagen Inc. does. For a patient with a chronic, debilitating autoimmune condition, an earlier, more accurate diagnosis means starting the right treatment sooner, which drastically changes their quality of life. The company's focus on this is supported by their active role in the scientific community.

A concrete example of this commitment is their research presence at the 2025 American College of Rheumatology (ACR) Convergence meeting. Exagen Inc. announced the acceptance of six abstracts for presentation, including a featured plenary presentation in collaboration with Johns Hopkins University. This research focuses on a urinary biomarker panel for managing Lupus Nephritis, which is a severe complication of lupus. This level of collaboration and presentation shows they are not just selling tests; they are actively driving the science that leads to better patient management and, ultimately, improved outcomes.

Exagen Inc. (XGN) Vision Statement

You're looking for a clear map of where Exagen Inc. is headed, and that starts with their vision. Their core ambition is simple but powerful: to be a leading provider of diagnostic and prognostic solutions in the field of autoimmune disease. This isn't just a feel-good statement; it's a strategic target that aligns directly with their financial performance and product focus.

This vision is underpinned by a push for precision medicine-using innovative biomarker discovery and testing technologies to drive advancements. For the investor, this focus on innovation is key, as it's what drives the growth in their flagship product, AVISE® CTD. The company is guiding for 2025 full-year revenue between $65 million and $70 million, which shows they are scaling their market leadership in a measurable way.

The vision also involves empowering physicians with the tools they need to personalize treatment strategies, which directly supports their average selling price (ASP). In the third quarter of 2025, the trailing-twelve-month ASP for the AVISE CTD test expanded to $441, a clear indicator that clinicians are valuing these advanced, personalized insights. That's a strong signal of product utility.

Driving Advancements in Precision Medicine

The vision is realized through continuous investment in their diagnostic platform. Precision medicine, in this context, means moving beyond general diagnosis to offering specific, actionable data that guides drug therapy and disease management. This is how they create a durable competitive advantage.

• Discover new biomarkers, not just confirm old ones.
• Enhance existing tests for greater accuracy and speed.
• Develop platforms for complex conditions like lupus nephritis.

Their recent commercial launch of seronegative rheumatoid arthritis (RA) markers for anti-PAD4, an enhancement to the AVISE CTD panel, is a perfect, concrete example of this vision in action. They are defintely moving the needle.

Empowering Physicians with Personalized Tools

A vision of leadership requires more than just a great product; it demands utility. Exagen Inc. aims to be the go-to resource for rheumatologists, offering clarity in decision-making for complex conditions like lupus and Sjögren's syndrome. The value proposition is early and accurate diagnosis, which leads to better patient outcomes and, critically, reduces the long-term cost of care for the healthcare system.

Here's the quick math: Q3 2025 saw AVISE CTD test volume grow by 16% compared to the same quarter in 2024, demonstrating that physicians are rapidly adopting these personalized tools. This volume increase, coupled with the higher ASP, is the engine that could get them to positive adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) in the fourth quarter, at the high end of their revenue guidance. That's the real-world impact of their vision.

Exagen Inc.'s Mission: Transforming the Care Continuum

The mission statement is the daily action plan that supports the long-term vision: To transform the care continuum for patients with autoimmune diseases. This mission is about solving the immediate, painful problems in the patient journey, from initial symptoms to long-term monitoring. It's about providing the right information at the right time.

The mission is executed through their innovative testing portfolio, which is designed to provide clarity in autoimmune disease decision-making and improve clinical outcomes. The company's nine-month revenue for 2025 was $49.944 million, a testament to the market's reliance on their diagnostic solutions to achieve this transformation. The mission isn't abstract; it's a revenue driver.

If you want to understand the full context of this mission, you might be interested in Exagen Inc. (XGN): History, Ownership, Mission, How It Works & Makes Money. The company's dedication to rheumatic diseases, delivering precise and timely results, is the operational core of this mission. They are focused on making a difference where the need is greatest.

Core Values: The Operational Guardrails

A company's values tell you how they plan to achieve their mission and vision. Exagen Inc. operates with four primary core values: Innovation, Integrity, Collaboration, and a Patient-Centric Approach. These aren't posters on a wall; they are the filters for every decision, from R&D spending to sales strategy.

Innovation is their lifeblood, as a diagnostics company. It means constantly investing in research to stay ahead of the curve, like their ongoing development of a lupus nephritis platform. You can't be a leader in a fast-moving field without it.

Integrity and Collaboration are crucial for building trust with both physicians and payers. They need to ensure their test results are reliable and that they work with the broader medical community-including presenting six abstracts at the American College of Rheumatology Conference in Q3 2025. This collaboration validates their science.

Finally, a Patient-Centric Approach is the moral compass. This value ensures that every test, every development, is ultimately focused on transforming care for people with chronic and debilitating autoimmune conditions. It's the human element that makes the financial investment worthwhile.

Exagen Inc. (XGN) Core Values

You're looking for a clear read on Exagen Inc. (XGN)'s foundation, and honestly, the mission and values are the bedrock for any long-term investment thesis. My two decades in this space, including time at firms like BlackRock, tell me that a company's stated values must map directly to its operational and financial results. Exagen's core values-Innovation, Patient Outcomes, and Accountability-aren't just posters on a wall; they are driving the company's 2025 performance.

The near-term opportunity here is tied to their ability to execute on these values, especially as they push toward profitability. You can get a deeper dive into who is betting on this execution by Exploring Exagen Inc. (XGN) Investor Profile: Who's Buying and Why?

Innovation and Research Leadership

Innovation is the lifeblood of a diagnostics company, especially one focused on complex autoimmune diseases. This value means Exagen Inc. is committed to continuous research and development (R&D) to create novel biomarkers (biological markers) and testing methodologies. If they stop innovating, their flagship AVISE® testing portfolio becomes obsolete, so this is a critical focus for investors.

The clearest proof of this commitment in 2025 is the commercial launch of the seronegative Rheumatoid Arthritis (RA) anti-PAD4 markers in the third quarter. This isn't just a new test; it's an expansion into a previously underserved market segment, which is where the real growth potential lies. Here's the quick math on the impact:

• New biomarkers drove an incremental revenue per test, helping the trailing 12-month Average Selling Price (ASP) for AVISE CTD reach $441 per test as of Q3 2025.
• The expansion into new territories is defintely paying off, allowing them to target increased penetration into the RA market.

What this estimate hides is the long R&D pipeline that supports this launch, but the market is rewarding the commercialization success now.

Unwavering Focus on Patient Outcomes

For a company in the autoimmune space, the ultimate measure of value isn't just revenue; it's the clinical utility-how much the test changes a doctor's decision and improves a patient's life. Exagen Inc. frames its mission around 'transforming the care continuum,' which is a plain-English way of saying they want to get patients diagnosed faster and more accurately.

The company's commitment to patient outcomes is demonstrated by the clinical impact of their AVISE® CTD test, which has been reported to influence treatment decisions in approximately 90% of cases. This high utility rate is what drives physician adoption and, consequently, test volume. In Q3 2025, they saw AVISE CTD test volume grow by a strong 16% compared to the same period in 2024, a direct result of rheumatologists trusting the clarity their tests provide.

This value is also upheld by maintaining their CLIA-certified and CAP-accredited laboratory standards, which ensures the precise and timely results that clinicians need for earlier intervention.

Accountability and Sustainable Growth

As a financial analyst, I see accountability as the value that bridges clinical success to shareholder return. It means setting clear financial targets and executing against them, especially the tough goal of achieving profitability. Exagen Inc. has been very transparent about this in 2025.

The company's financial results for the 2025 fiscal year show a clear trajectory toward this goal. They reported a record total revenue of $17.2 million in Q3 2025, marking a 38% year-over-year increase. More importantly, they've been diligently managing their operational spend:

• The Adjusted EBITDA loss for Q3 2025 was reduced to $(1.9) million, a significant improvement.
• Management reiterated their full-year 2025 revenue guidance of $65 million to $70 million.
• They are projecting to hit positive Adjusted EBITDA in Q4 2025 at the high end of that revenue range. That's the key metric.

Ending Q3 2025 with a cash position of $35.7 million also shows financial discipline, giving them the runway to execute their growth plans without immediate capital concerns. They are focused on operational efficiency, and the numbers reflect that push.